In a study involving a cohort of 21 patients with stage II or III melanoma treated with low-dose IFN-α for more than 12 months, blood samples were obtained before treatment, and at 3, 6, 9, and 12 months after initiation of treatment. The gene discussed is IFNA2; the disease is melanoma.